Johdo O, Ishikura T, Yoshimoto A, Takeuchi T
Central Research Laboratories, Mercian Corporation, Fujisawa, Japan.
J Antibiot (Tokyo). 1991 Oct;44(10):1110-20. doi: 10.7164/antibiotics.44.1110.
Five mutant (or variant) strains producing new anthracycline antibiotics were derived from Streptomyces violaceus A262 by mutagenesis treatment. Strain SE1-625 showed a limited production of three known beta-rhodomycinone diglycosides while the parent strain produced numerous unidentified beta-rhodomycinone glycosides. Strain SU2-730 was an antibiotic-blocked mutant which produced only epsilon-rhodomycinone glycosides (named epelmycins). Strains SC-7 and SE2-2385 were variants which produced alpha-citromycinone glycosides (named yellamycins) and beta-isorhodomycinone glycosides (named obelmycins), respectively. Strain SE2-2385-A1 produced alpha 2-rhodomycinone glycosides (named alldimycins). Glycosidation-less mutants which accumulated only aglycone were also obtained. Isolation of these mutants or variants and preliminary identification of their anthracycline products are described.
通过诱变处理，从紫色链霉菌A262中获得了5株产生新蒽环类抗生素的突变（或变体）菌株。SE1-625菌株产生三种已知的β-玫瑰霉素酮二糖苷的产量有限，而亲本菌株产生大量未鉴定的β-玫瑰霉素酮糖苷。SU2-730菌株是一种抗生素阻断突变体，仅产生ε-玫瑰霉素酮糖苷（命名为埃佩霉素）。SC-7和SE2-2385菌株是变体，分别产生α-柠檬霉素酮糖苷（命名为耶拉霉素）和β-异玫瑰霉素酮糖苷（命名为奥贝霉素）。SE2-2385-A1菌株产生α2-玫瑰霉素酮糖苷（命名为阿尔迪霉素）。还获得了仅积累苷元的无糖基化突变体。描述了这些突变体或变体的分离及其蒽环类产物的初步鉴定。
